Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 1,201–1,260 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…f colorectal cancer (CRC) due to mismatch repair gene variants. Mesalamine (5-ASA, 5-aminosalicylic acid), used safely in patients with ul…
…ugust 22, 2025.Results Among 90 evaluable patients treated with ELI-002 7P, 98.9% (89/90) induced mKRAS-specific T cells post-vaccination …
…and a ‘cold’ tumor microenvironment (TME).2 We hypothesize that FX-909, an oral first-in-class inhibitor of PPARG, exerts antitumor ac…
…results of a randomized, open-label pilot study evaluating oral vancomycin, a non-absorbed, Gram-positive-targeting antibiotic, combined w…
…ed favorable, with no new safety signals identified.Conclusions Ivonescimab plus chemotherapy demonstrated a clinically meaningful and stat…
…8.9% were male and 51.1% were female. The most common ICIs were Pembrolizumab (16276, 45.38%), Nivolumab (10548, 29.41%), Ipilimumab (3120, 8…
…tage III NSCLC who were treated with chemoradiation followed by durvalumab. Data collection included baseline characteristics, treatment p…
…s the responsiveness of CD8+ T-cells with exhausted phenotypes. Butyrate demonstrated an ability to alter the expression of immune check…
… suppression and eliminates tumors in preclinical mouse models. CTX-10726 is currently undergoing IND-enabling studies to determine the o…
…ivo studies demonstrated 48% tumor growth inhibition (TGI) with AVA-ADR-001 monotherapy, compared to 35% TGI with anti-PD-1 alone. Combinat…
…eduction in proliferation within a subset of colon tumours upon SU1644 treatment, a potential strategy to target metastasis in right-s…
…ared to both aforementioned reagents.Conclusions In conclusion, Travirtide is a highly potent novel transduction enhancer with very low cy…